Adjuvant therapy in renal cell carcinoma: Does higher risk for recurrence improve the chance for success?

R. A. Figlin, B. C. Leibovich, G. D. Stewart, S. Negrier

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

The success of targeted therapies, including inhibitors of the vascular endothelial growth factor pathway or the mammalian target of rapamycin, in the treatment of metastatic renal cell carcinoma led to interest in testing their efficacy in the adjuvant setting. Results from the first trials are now available, with other studies due to report imminently. This review provides an overview of adjuvant targeted therapy in renal cell carcinoma, including interpretation of currently available conflicting data and future direction of research. We discuss the key differences between the completed targeted therapy adjuvant trials, and highlight the importance of accurately identifying patients who are likely to benefit from adjuvant treatment. We also consider reasons why blinded independent radiology review and treatment dose may prove critical for adjuvant treatment success. The implications of using disease-free survival as a surrogate end point for overall survival from the patient perspective and measurement of health benefit have recently been brought into focus and are discussed. Finally, we discuss how the ongoing adjuvant trials with targeted therapies and checkpoint inhibitors may improve our understanding and ability to prevent tumor recurrence after nephrectomy in the future.

Original languageEnglish (US)
Pages (from-to)324-331
Number of pages8
JournalAnnals of Oncology
Volume29
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Renal Cell Carcinoma
Recurrence
Therapeutics
Insurance Benefits
Sirolimus
Nephrectomy
Radiology
Vascular Endothelial Growth Factor A
Disease-Free Survival
Biomarkers
Survival
Research
Neoplasms

Keywords

  • Adjuvant therapy
  • ASSURE
  • PROTECT
  • Renal cell carcinoma
  • S-TRAC

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Adjuvant therapy in renal cell carcinoma : Does higher risk for recurrence improve the chance for success? / Figlin, R. A.; Leibovich, B. C.; Stewart, G. D.; Negrier, S.

In: Annals of Oncology, Vol. 29, No. 2, 01.02.2018, p. 324-331.

Research output: Contribution to journalReview article

Figlin, R. A. ; Leibovich, B. C. ; Stewart, G. D. ; Negrier, S. / Adjuvant therapy in renal cell carcinoma : Does higher risk for recurrence improve the chance for success?. In: Annals of Oncology. 2018 ; Vol. 29, No. 2. pp. 324-331.
@article{97ed6d0f74424fd091eb7d99377b56e4,
title = "Adjuvant therapy in renal cell carcinoma: Does higher risk for recurrence improve the chance for success?",
abstract = "The success of targeted therapies, including inhibitors of the vascular endothelial growth factor pathway or the mammalian target of rapamycin, in the treatment of metastatic renal cell carcinoma led to interest in testing their efficacy in the adjuvant setting. Results from the first trials are now available, with other studies due to report imminently. This review provides an overview of adjuvant targeted therapy in renal cell carcinoma, including interpretation of currently available conflicting data and future direction of research. We discuss the key differences between the completed targeted therapy adjuvant trials, and highlight the importance of accurately identifying patients who are likely to benefit from adjuvant treatment. We also consider reasons why blinded independent radiology review and treatment dose may prove critical for adjuvant treatment success. The implications of using disease-free survival as a surrogate end point for overall survival from the patient perspective and measurement of health benefit have recently been brought into focus and are discussed. Finally, we discuss how the ongoing adjuvant trials with targeted therapies and checkpoint inhibitors may improve our understanding and ability to prevent tumor recurrence after nephrectomy in the future.",
keywords = "Adjuvant therapy, ASSURE, PROTECT, Renal cell carcinoma, S-TRAC",
author = "Figlin, {R. A.} and Leibovich, {B. C.} and Stewart, {G. D.} and S. Negrier",
year = "2018",
month = "2",
day = "1",
doi = "10.1093/annonc/mdx743",
language = "English (US)",
volume = "29",
pages = "324--331",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Adjuvant therapy in renal cell carcinoma

T2 - Does higher risk for recurrence improve the chance for success?

AU - Figlin, R. A.

AU - Leibovich, B. C.

AU - Stewart, G. D.

AU - Negrier, S.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - The success of targeted therapies, including inhibitors of the vascular endothelial growth factor pathway or the mammalian target of rapamycin, in the treatment of metastatic renal cell carcinoma led to interest in testing their efficacy in the adjuvant setting. Results from the first trials are now available, with other studies due to report imminently. This review provides an overview of adjuvant targeted therapy in renal cell carcinoma, including interpretation of currently available conflicting data and future direction of research. We discuss the key differences between the completed targeted therapy adjuvant trials, and highlight the importance of accurately identifying patients who are likely to benefit from adjuvant treatment. We also consider reasons why blinded independent radiology review and treatment dose may prove critical for adjuvant treatment success. The implications of using disease-free survival as a surrogate end point for overall survival from the patient perspective and measurement of health benefit have recently been brought into focus and are discussed. Finally, we discuss how the ongoing adjuvant trials with targeted therapies and checkpoint inhibitors may improve our understanding and ability to prevent tumor recurrence after nephrectomy in the future.

AB - The success of targeted therapies, including inhibitors of the vascular endothelial growth factor pathway or the mammalian target of rapamycin, in the treatment of metastatic renal cell carcinoma led to interest in testing their efficacy in the adjuvant setting. Results from the first trials are now available, with other studies due to report imminently. This review provides an overview of adjuvant targeted therapy in renal cell carcinoma, including interpretation of currently available conflicting data and future direction of research. We discuss the key differences between the completed targeted therapy adjuvant trials, and highlight the importance of accurately identifying patients who are likely to benefit from adjuvant treatment. We also consider reasons why blinded independent radiology review and treatment dose may prove critical for adjuvant treatment success. The implications of using disease-free survival as a surrogate end point for overall survival from the patient perspective and measurement of health benefit have recently been brought into focus and are discussed. Finally, we discuss how the ongoing adjuvant trials with targeted therapies and checkpoint inhibitors may improve our understanding and ability to prevent tumor recurrence after nephrectomy in the future.

KW - Adjuvant therapy

KW - ASSURE

KW - PROTECT

KW - Renal cell carcinoma

KW - S-TRAC

UR - http://www.scopus.com/inward/record.url?scp=85042566813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042566813&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdx743

DO - 10.1093/annonc/mdx743

M3 - Review article

C2 - 29186296

AN - SCOPUS:85042566813

VL - 29

SP - 324

EP - 331

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 2

ER -